Modified AAV Capsid Proteins Enhance Retinal Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adeno-associated virus (AAV) vectors face challenges in achieving efficient transduction of the retina and retinal pigment epithelium through intravitreal delivery, primarily due to the barrier posed by the inner limiting membrane.
Innovation Solution
Modification of AAV capsid proteins by introducing specific substitutions at certain amino acid residues, such as K530 in AAV4 and K517 in AAV5, to enhance heparan sulfate binding, thereby improving the transduction efficiency of AAV vectors into retinal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If intravitreal delivery of AAV vectors is used, then the injection route is less invasive, but transduction efficiency is poor due to the inner limiting membrane barrier
Solution Approach 1:
The patent modifies the AAV capsid protein by introducing specific amino acid substitutions (K530 in AAV4 and K517 in AAV5) to alter the binding properties of the vector. These parameter changes in the capsid structure enhance heparan sulfate binding affinity, enabling the vector to overcome the inner limiting membrane barrier and achieve efficient retinal transduction through intravitreal delivery
Solution Approach 2:
The patent creates a composite functionality by combining the AAV vector with modified capsid properties that specifically interact with heparan sulfate. The substituted capsid proteins form a composite interaction mechanism with the inner limiting membrane, allowing the vector to both navigate through and efficiently transduce retinal cells while maintaining the less invasive intravitreal injection route
2Reliability
If AAV capsid proteins are modified with specific substitutions, then heparan sulfate binding is enhanced, but the complexity of vector development increases
Solution Approach 1:
The patent applies local quality modification by introducing substitutions at specific, localized positions (K530 in AAV4 and K517 in AAV5) within the capsid protein sequence. Rather than modifying the entire capsid structure, these targeted local changes at specific amino acid residues are sufficient to enhance heparan sulfate binding affinity while maintaining overall capsid integrity and function
Solution Approach 2:
The patent employs parameter changes by systematically modifying specific amino acid residues in the capsid protein sequence. These controlled parameter changes at defined positions allow for enhanced binding properties without requiring complete redesign of the vector system, thus improving reliability while managing development complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified AAV capsid proteins with enhanced heparan sulfate binding capabilities significantly improve the transduction efficiency of AAV vectors into retinal cells, overcoming the barrier of the inner limiting membrane and achieving desirable targeting of retinal tissues.
Implementation Method 1
Modification of AAV capsid proteins by introducing specific substitutions at certain amino acid residues, such as K530 in AAV4 and K517 in AAV5, to enhance heparan sulfate binding
Data Source
AI summary
The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.